The burden of inflammatory bowel disease (IBD) in older adults (ie, aged over 60 years old)
is increasing due to a combination of an ageing population with compounding prevalence of …

Ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory bowel diseases
(IBD) of unknown etiology, characterized by repeated relapse and remission. The efficacy of …

Background Vedolizumab registration trials were the first to include elderly patients with
moderate‐to‐severe ulcerative colitis (UC) or Crohn's disease (CD), but few real‐life data …

Background Few data are available on the effects of age and comorbidity on treatment
outcomes of vedolizumab and ustekinumab in inflammatory bowel disease (IBD). Aims To …

Thiopurines have been a cornerstone in the treatment of inflammatory bowel disease (IBD).
Although they have been used for more than 50 years, there are still some unsolved issues …

Background Anti-tumour necrosis factor (anti-TNF) agents are associated with increased
infection risk among elderly inflammatory bowel disease (IBD) patients, and thus, alternative …

The number of patients with inflammatory bowel disease (IBD) approaching an older age,
together with the number of over-60-year-old patients newly diagnosed with IBD, is steadily …

The ENEIDA registry, promoted by the Spanish Working Group on Crohn's Disease and
Ulcerative Colitis (GETECCU), was created in 2005 by a group of gastroenterologists …

Objective Anti-tumour necrosis factor (TNF) agents are associated with increased infection
risk among elderly IBD patients, but little is known about non anti-TNF biologics in this …

Background The incidence and prevalence of inflammatory bowel diseases (IBD) in older
adults are rising. There is a limited comparative assessment of risk of disease-and treatment …